scholarly journals Antisense oligonucleotide targeting eukaryotic translation initiation factor 4E reduces growth and enhances chemosensitivity of non-small-cell lung cancer cells

2015 ◽  
Vol 22 (8) ◽  
pp. 396-401 ◽  
Author(s):  
S C Thumma ◽  
B A Jacobson ◽  
M R Patel ◽  
B W Konicek ◽  
M J Franklin ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Cells ◽  
Translation Initiation ◽  
Antisense Oligonucleotide ◽  
Small Cell ◽  
Translation Initiation Factor ◽  
Initiation Factor ◽  
Small Cell Lung ◽  
Eukaryotic Translation ◽  
Eukaryotic Translation Initiation

scholarly journals N1-Guanyl-1,7-Diaminoheptane Sensitizes Estrogen Receptor Negative Breast Cancer Cells to Doxorubicin by Preventing Epithelial-Mesenchymal Transition through Inhibition of Eukaryotic Translation Initiation Factor 5A2 Activation

2015 ◽  
Vol 36 (6) ◽  
pp. 2494-2503 ◽  
Author(s):  
Yu Liu ◽  
Rongrong Liu ◽  
Peifen Fu ◽  
Feiya Du ◽  
Yun Hong ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Translation Initiation ◽  
Breast Cancer Cells ◽  
Epithelial Mesenchymal Transition ◽  
Translation Initiation Factor ◽  
Initiation Factor ◽  
Mesenchymal Transition ◽  
Eukaryotic Translation ◽  
Eukaryotic Translation Initiation

Background: Approximately 30% of breast cancer does not express the estrogen receptor (ER), which is necessary for endocrine-based therapy approaches. Many studies demonstrated that eukaryotic translation initiation factor 5A2 (eIF5A2) serves as a proliferation-related oncogene in tumorigenic processes. Methods: The present study used cell viability assays, EdU incorporation assays, western blot, and immunofluorescence to explore whether N1-guanyl-1,7-diaminoheptane (GC7), which inhibits eIF5A2 activation, exerts synergistic cytotoxicity with doxorubicin in breast cancer. Results: We found that GC7 enhanced doxorubicin cytotoxicity in ER-negative HCC1937 cells but had little effect in ER-positive MCF-7 and Bcap-37 cells. Administration of GC7 reversed the doxorubicin-induced epithelial-mesenchymal transition (EMT) in ER-negative breast cancer cells. Knockdown of eIF5A2 by siRNA inhibited the doxorubicin-induced EMT in ER-negative HCC1937 cells. Conclusion: These data demonstrated that GC7 combination therapy may enhance the therapeutic efficacy of doxorubicin in estrogen negative breast cancer cells by preventing EMT through inhibition of eIF5A2 activation.

Sign in / Sign up

Export Citation Format

Share Document